Home›Stock Screener›Biogen Pharmachem›Financial Statements

Biogen Pharmachem Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2025, Biogen Pharmachem (BIOGEN) reported revenue ₹1 Cr, net profit ₹0 Cr and EPS ₹0.00. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore BIOGEN value investing to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Balance Sheet Ratios

Equity Ratio 100.00% 2025 data
Asset Turnover 0.01 2025 data

BIOGEN Revenue, Net Profit & EBITDA — Year-on-Year Growth

BIOGEN YoY (March 2024 vs March 2025) — revenue -50.0%, net profit -100.0%, EBITDA -100.0%, expenses +100.0%. Review BIOGEN PE ratio trends to evaluate earnings-based valuation against sector peers.

Revenue Growth
-50.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
+100.0%
Year-over-Year
Assets Growth
+7.6%
Year-over-Year
Equity Growth
+7.6%
Year-over-Year
Operating Cash Flow Growth
-150.0%
Year-over-Year
Investing Cash Flow Growth
-1550.0%
Year-over-Year

BIOGEN Income Statement — Revenue, EBITDA & Net Profit

Biogen Pharmachem revenue ₹1 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (2025). For live price, earnings ratios and company overview, see BIOGEN share price screener.

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 1 2 1 3 2 0 1 0 0 0 0
Expenses 2 1 1 3 3 0 1 7 0 0 0
EBITDA 0 2 1 0 -2 0 0 -7 0 0 0
Operating Profit Margin % 0.00% 0.00% 0.00% -1.00% -99.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 2 1 0 -2 0 0 -7 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0
Net Profit 0 2 1 0 -2 0 0 -7 0 0 0
Earnings Per Share (₹) 0.00 0.03 0.01 0.00 -0.02 0.00 0.00 -0.10 0.00 0.00 0.00

BIOGEN Balance Sheet — Assets, Liabilities & Shareholders' Equity

BIOGEN total assets ₹99 Cr, total equity ₹99 Cr, total liabilities ₹ Cr (2026).

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 99 92 57 55 55 54 56 58 56 63 69 74
Current Assets 1 3 0 0 2 3 8 8 7 0 14 29
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0 0
Capital Work in Progress 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 24 5 9 7 10 6 6 4 22 14 23
Other Assets 0 68 51 46 48 45 50 51 52 41 55 51
LIABILITIES
Total Liabilities
Current Liabilities 0 0 0 0 0 0 0 2 2 2 8 9
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 99 92 57 55 54 54 56 54 54 61 61 61
Share Capital 90 65 65 65 65 65 65 65 65 65 65 65
Reserves & Surplus 9 -9 -9 -11 -11 -11 -10 -11 -11 -4 -4 -4

BIOGEN Cash Flow Statement — Operating, Investing & Financing

Biogen Pharmachem operating cash flow ₹-1 Cr, investing ₹-33 Cr, financing ₹36 Cr, net cash flow ₹2 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -1 2 2 1 4 -1 0 -14 0 5 -7
Investing Activities -33 -2 -2 -1 -4 2 -1 14 4 17 17
Financing Activities 36 0 0 0 0 0 1 -1 -4 -22 -11
Net Cash Flow 2 0 0 0 0 0 0 0 0 0 -1